Saturday December 15, 2018 00:24

Heathcare Press Release : 27 Nov 2018

American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults Heathcare—27 Nov 18

A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type 2 diabetes and